Semuloparin Prophylaxis Effective in Cancer Patients

Share this article:
Semuloparin Prophylaxis Effective in Cancer Patients
Semuloparin Prophylaxis Effective in Cancer Patients

(HealthDay News) -- Semuloparin, a hemisynthetic, ultra-low-molecular-weight heparin, reduces the incidence of thromboembolic events in cancer patients receiving chemotherapy, with no increased risk of a major bleeding event, according to a study published in the Feb. 16 issue of the New England Journal of Medicine.

Giancarlo Agnelli, M.D., of the University of Perugia in Italy, and colleagues conducted a double-blind, multicenter trial in patients with metastatic or locally advanced solid tumors who were beginning to receive a course of chemotherapy. Patients were randomly assigned to receive either subcutaneous semuloparin (20 mg once daily; 1,608 patients) or placebo (1,604 patients) until there was a change of chemotherapy regimen.

The researchers found that, during a mean treatment duration of 3.5 months, venous thromboembolism occurred in significantly fewer patients receiving semuloparin versus placebo (1.2 versus 3.4 percent; hazard ratio [HR], 0.36; P < 0.001). There was consistent efficacy among subgroups defined by origin and stage of cancer, and by baseline risk of venous thromboembolism. The incidence of clinically relevant bleeding was 2.8 and 2.0 percent in the semuloparin and placebo groups, respectively (HR, 1.40; 95 percent confidence interval [CI], 0.89 to 2.21) with major bleeding occurring in 1.2 percent of patients receiving semuloparin and 1.1 percent receiving placebo (HR, 1.05; 95 percent CI, 0.55 to 1.99). All other adverse events had similar incidences in the two study groups.

"Semuloparin reduces the incidence of thromboembolic events in patients receiving chemotherapy for cancer, with no apparent increase in major bleeding," the authors write.

The study was funded by Sanofi; several authors disclosed financial relationships with pharmaceutical companies, including Sanofi.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Statins may lower progression risk for renal cancer

Statins may lower progression risk for renal cancer

Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Cancer patients require anxiety and depression screening

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.